article thumbnail

STAT+: Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves second RSV vaccine

STAT

… Coherus BioSciences plans to sell a biosimilar version of Humira at a steep discount, STAT reports , and the company will work with Mark Cuban’s generic drug company to make the medicine available directly to consumers for even less. Neither vaccine is currently available for use.

Vaccines 246
article thumbnail

What to know about vaccine ingredients: Aluminum and thimerosal

PhRMA

It’s natural for people to have questions about vaccines and how each ingredient plays a role. Each ingredient included in a vaccine plays a necessary role in ensuring a vaccine’s safety, quality or effectiveness.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Barriers are limiting UK childhood vaccination, say doctors

pharmaphorum

The Vaccination in the UK: Access, uptake and equity (PDF) report notes that, over the last decade, the uptake of vaccines in the UK has stalled and is in many cases falling, leading to outbreaks of preventable diseases such as measles and whooping cough.

article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108
article thumbnail

Health Canada consults on transition of interim order drugs, vaccines, and medical devices to permanent approval pathways

Pharma in Brief

Any authorization for drugs, vaccines, and medical devices issued pursuant to the interim orders are also set to terminate when the respective interim order expires or is withdrawn. Drugs and Vaccines. Both interim orders are set to expire 1 year after they were issued, or sooner if withdrawn by the Minister.

article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period.

article thumbnail

Now Available! Announcing the Vaccine Patent Litigation and Vaccine Patent PTAB Trackers

Big Molecule Watch

As Big Molecule Watch continues to push past the bounds of biosimilars and into biologics, we are proud to announce the publication of two additional trackers concerning vaccines: the Vaccine Patent Litigation tracker and the Vaccine Patent PTAB tracker. The post Now Available!